Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | CD19/CD22 CAR T cells |
| Trade Name | |
| Synonyms | Autologous CD19/CD22 Chimeric Antigen Receptor T-cells |
| Drug Descriptions |
CD19/CD22 CAR T cells are human T-cells engineered to express a CD19 and CD22 chimeric receptor, which may lead to cytotoxic immune response against tumor cells expressing CD19 and CD22 (PMID: 32005917). |
| DrugClasses | CD19 Immune Cell Therapy 72 CD22 Immune Cell Therapy 13 |
| CAS Registry Number | NA |
| NCIT ID | C142834 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| CD19/CD22 CAR T cells | CD19/CD22 CAR T cells | 0 | 6 |
| CD19/CD22 CAR T cells + Cyclophosphamide + Fludarabine | CD19/CD22 CAR T cells Cyclophosphamide Fludarabine | 0 | 0 |